Neuropathologic Alterations in Mild Cognitive Impairment: A Review
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Mild cognitive impairment (MCI), the earliest clinically detectable phase of the trajectory toward dementia and Alzheimer's disease (AD), led to the need for even earlier detection and prevention of AD. Although it is a clinical diagnosis, its underlying neuropathological findings are just being defined. MCI is best studied in longitudinally followed patients in centers that are experienced in dementing disorders. In this review of the few major clinical-pathological reports of longitudinally followed patients, it appears that most autopsied amnestic MCI (aMCI) patients are on a pathway toward AD. Neurofibrillary pathology in entorhinal cortex, hippocampus, and amygdala--not amyloid plaques--is the major substrate for aMCI and for memory decline. In addition, many MCI patients have other concomitant pathological alterations, the most common of which are strokes, but also include argyrophilic grains and Lewy bodies. These findings are not surprising because most MCI autopsied cases have been in the older (80 to 90 year) range where these findings are common. In early AD, the phase following MCI, the significant change is an increase in neurofibrillary tangles in the neocortex that correlates with an increase in Braak score and the observed clinical progression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“AD pathology occurs well before (up to two decades) the onset of clinical symptoms2–4.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [3]
In the citing paper
“It has been estimated that approximately 15 percent of people with aMCI progress to AD annually3.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [3]
In the citing paper
“Indeed, the first pathological insults to neurons in AD and aMCI occur at pre- and post-synaptic membranes1,3.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [3]
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 4×
“The National Institute on Aging and Reagan Institute (NIA-RI) criteria, developed in 1997 [9], use the CERAD plaque score and the Braak and Braak score to reach a likelihood of the diagnosis of AD.”
ResultInfluentialMirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490
Diagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499
Observations on the brains of demented old people
Tomlinson, B. E., Blessed, G., & Roth, M. (1970) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(70)90063-8 · Cited by 2,084 · cited 1×
“[2] in two seminal publications to describe that the”
BackgroundMild Cognitive Impairment Represents Early-Stage Alzheimer Disease
Morris, J. C., Storandt, M., Miller, J. P., McKeel, D. W., Price, J. L., Rubin, E. H., & Berg, L. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.397 · Cited by 1,851 · cited 2×
“In another report from Washington University’s Alzheimer’s Disease Research Center [17], they found that in six subjects with CDR scores of 0.5 with uncertain dementia at entry into this study, all had neuropathological AD at autopsy.”
BackgroundInfluentialHYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542
Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment
Jack, C. R., Petersen, R. C., Xu, Y. C., O’Brien, P. C., Smith, G. E., Ivnik, R. J., Boeve, B. F., Waring, S. C., Tangalos, E. G., & Kokmen, E. (1999) · Neurology · doi:10.1212/wnl.52.7.1397 · Cited by 1,404
Reiman, E. M., Caselli, R. J., Yun, L. S., Chen, K., Bandy, D., Minoshima, S., Thibodeau, S. N., & Osborne, D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603213341202 · Cited by 1,366
Cited by
Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease
Butterfield, D. A., & Halliwell, B. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0132-6 · Cited by 1,954
Machine learning framework for early MRI-based Alzheimer's conversion prediction in MCI subjects
Moradi, E., Pepe, A., Gaser, C., Huttunen, H., & Tohka, J. (2015) · NeuroImage · doi:10.1016/j.neuroimage.2014.10.002 · Cited by 708
“Mild cognitive impairment (MCI) is a transitional stage between age-related cognitive decline and AD, and the earliest clinically detectable stage of progression towards dementia or AD (Markesbery, 2010).”
Neuropathology of sporadic Parkinson's disease: Evaluation and changes of concepts
Jellinger, K. A. (2012) · Movement Disorders · doi:10.1002/mds.23795 · Cited by 451
Saygin, Z. M., Kliemann, D., Iglesias, J. E., van der Kouwe, A. J. W., Boyd, E., Reuter, M., Stevens, A., Van Leemput, K., McKee, A., Frosch, M. P., et al. (2017) · NeuroImage · doi:10.1016/j.neuroimage.2017.04.046 · Cited by 467
“For the ADNI comparison, we expected gross anatomical differences between the pathological and the control group, given the neuropathology in AD and MCI (Markesbery, 2010; Yilmazer-Hanke, 1998).”
BackgroundMethodInfluentialSpasov, S., Passamonti, L., Duggento, A., Liò, P., & Toschi, N. (2019) · NeuroImage · doi:10.1016/j.neuroimage.2019.01.031 · Cited by 425
Lin, W., Tong, T., Gao, Q., Guo, D., Du, X., Yang, Y., Guo, G., Xiao, M., Du, M., Qu, X., et al. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00777 · Cited by 390
“Mild cognitive impairment (MCI) is known as the transitional stage between normal cognition and dementia (Markesbery, 2010), about 10–15% individuals with MCI progress to AD per year (Grundman et al., 2004).”
BackgroundEmerging histomorphologic phenotypes of chronic traumatic encephalopathy in American athletes
Omalu, B., Bailes, J., Hamilton, R. L., Kamboh, M. I., Hammers, J., Case, M., & Fitzsimmons, R. (2011) · Neurosurgery · doi:10.1227/neu.0b013e318212bc7b · Cited by 381
Perluigi, M., Di Domenico, F., & Butterfield, D. A. (2024) · Physiological Reviews · doi:10.1152/physrev.00030.2022 · Cited by 282
Mild cognitive impairment: pathology and mechanisms
Mufson, E. J., Binder, L., Counts, S. E., DeKosky, S. T., deToledo-Morrell, L., Ginsberg, S. D., Ikonomovic, M. D., Perez, S. E., & Scheff, S. W. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0884-1 · Cited by 257
“A clinical pathologic study using a mixed cohort of MCI (aMCI and mdMCI) cases from the Rush Religious Orders Study (RROS), a clinical pathologic longitudinal study of aging and dementia [15, 109] found that ERC Ab-amyloid peptide load in MCI cases appeared intermediate between controls and early AD, but the differenc…”
Tau burden and the functional connectome in Alzheimer’s disease and progressive supranuclear palsy
Cope, T. E., Rittman, T., Borchert, R. J., Jones, P. S., Vatansever, D., Allinson, K., Passamonti, L., Vazquez Rodriguez, P., Bevan-Jones, W. R., O'Brien, J. T., et al. (2018) · Brain · doi:10.1093/brain/awx347 · Cited by 246
“…Alzheimer’s disease is sufficiently advanced to cause the symptoms of MCI, tau is generally already present to some degree throughout the neocortex (Markesbery, 2010), and therefore reaching a disease stage at which the number of neighbours more closely approximates the number of infected…”
BackgroundLipidomics of Human Brain Aging and Alzheimer's Disease Pathology
Naudí, A., Cabré, R., Jové, M., Ayala, V., Gonzalo, H., Portero-Otín, M., Ferrer, I., & Pamplona, R. (2015) · International Review of Neurobiology · doi:10.1016/bs.irn.2015.05.008 · Cited by 194
Predicting conversion from MCI to AD using resting-state fMRI, graph theoretical approach and SVM
Hojjati, S. H., Ebrahimzadeh, A., Khazaee, A., & Babajani-Feremi, A. (2017) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2017.03.006 · Cited by 193
Abrol, A., Bhattarai, M., Fedorov, A., Du, Y., Plis, S., & Calhoun, V. (2020) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2020.108701 · Cited by 182
Apolipoprotein E and oxidative stress in brain with relevance to Alzheimer's disease
Butterfield, D. A., & Mattson, M. P. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104795 · Cited by 188
Plasma microRNA biomarkers for detection of mild cognitive impairment
Sheinerman, K. S., Tsivinsky, V. G., Crawford, F., Mullan, M. J., Abdullah, L., & Umansky, S. R. (2012) · Aging · doi:10.18632/aging.100486 · Cited by 188
“Mild cognitive impairment (MCI) is usually defined as an intermediate state between normal aging, and AD and other dementias, representing the first stage when clinical symptoms become evident [3-5].”
BackgroundTheory of Mind in normal ageing and neurodegenerative pathologies
Kemp, J., Després, O., Sellal, F., & Dufour, A. (2012) · Ageing Research Reviews · doi:10.1016/j.arr.2011.12.001 · Cited by 163
Hippocampal plasticity during the progression of Alzheimer’s disease
Mufson, E. J., Mahady, L., Waters, D., Counts, S. E., Perez, S. E., DeKosky, S. T., Ginsberg, S. D., Ikonomovic, M. D., Scheff, S. W., & Binder, L. I. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.03.006 · Cited by 172
“…clinically diagnosed with no cognitive impairment (NCI) or MCI can exhibit SP and NFT pathology equal to or greater that that seen in mild to moderate AD, challenging the pathologically based idea that these lesions alone cause dementia (Mufson et al., 1999; Price et al., 2009; Markesbery, 2010).”
BackgroundMethodResultInfluentialA CNN based framework for classification of Alzheimer’s disease
AbdulAzeem, Y., Bahgat, W. M., & Badawy, M. (2021) · Neural Computing and Applications · doi:10.1007/s00521-021-05799-w · Cited by 171
Effects of aging on mindreading ability through the eyes: An fMRI study
Castelli, I., Baglio, F., Blasi, V., Alberoni, M., Falini, A., Liverta-Sempio, O., Nemni, R., & Marchetti, A. (2010) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2010.05.005 · Cited by 170
Ferrer, I. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.03.005 · Cited by 174
“…accompanying alteration in AD (Goedert, 1996; Duyckaerts and Dickson, 2003; Masters and Beyreuther, 2003; Lowe et al., 2008; Shepherd et al., 2009; Markesbery, 2010; Serrano-Pozo et al., 2011). b-amyloid deposits result from the proteolytic cleavage of the APP precursor by b-secretases (BACEs)…”
BackgroundReorganization of Functional Networks in Mild Cognitive Impairment
Buldú, J. M., Bajo, R., Maestú, F., Castellanos, N., Leyva, I., Gil, P., Sendiña-Nadal, I., Almendral, J. A., Nevado, A., del-Pozo, F., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019584 · Cited by 139
“Examples include neurofibrilary tangles, which affect communication, the loss of synaptic contacts or the accumulation of the beta-amyloid protein which tend to happen in the associative cortex such as the temporal or the parietal lobes in both AD and MCI patients [7,12,32].”
BackgroundVana, L., Kanaan, N. M., Ugwu, I. C., Wuu, J., Mufson, E. J., & Binder, L. I. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.07.044 · Cited by 138
“maintain cognitive capability in the presence of a significant pathological load.(75,76) A comparison between these cases and those that have a similar pathological load but a diagnosis of AD may help differentiate factors crucial to cognitive function from those less directly applicable, such as cognitive reserve or…”
BackgroundResultMagnetic resonance spectroscopy in mild cognitive impairment: Systematic review and meta-analysis
Tumati, S., Martens, S., & Aleman, A. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.08.004 · Cited by 143
Molecular and cellular pathophysiology of preclinical Alzheimer’s disease
Mufson, E. J., Ikonomovic, M. D., Counts, S. E., Perez, S. E., Malek-Ahmadi, M., Scheff, S. W., & Ginsberg, S. D. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.05.030 · Cited by 127
“3) as well as NFT pathology equal to or greater than what is often seen neuropathologically in mild to moderate AD, challenging the singular notion that these lesions alone drive dementia onset [21] [22] [23].”
Varied effects of age-related neuropathologies on the trajectory of late life cognitive decline
Boyle, P. A., Yang, J., Yu, L., Leurgans, S. E., Capuano, A. W., Schneider, J. A., Wilson, R. S., & Bennett, D. A. (2017) · Brain · doi:10.1093/brain/aww341 · Cited by 129
Barone, E., Di Domenico, F., Mancuso, C., & Butterfield, D. A. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.09.018 · Cited by 127
“Hippocampus is broadly recognized as amain target of neurodegenerative damage during AD progression, presenting increased levels of oxidative stress, neuronal loss and marked atrophy in respect to whole brain (Aksenov et al., 1995; Keller et al., 2005; Markesbery, 2010).”
López-González, I., Schlüter, A., Aso, E., Garcia-Esparcia, P., Ansoleaga, B., LLorens, F., Carmona, M., Moreno, J., Fuso, A., Portero-Otin, M., et al. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000176 · Cited by 125
Butterfield, D. A. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.06.006 · Cited by 126
“Mild cognitive impairment [12,13], particularly amnestic MCI, is arguably a prodromal form of AD.”
BackgroundBerchtold, N. C., Sabbagh, M. N., Beach, T. G., Kim, R. C., Cribbs, D. H., & Cotman, C. W. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.03.031 · Cited by 124
“While much is known about the clinical and neuropathological profiles of MCI (Markesbery, 2010,Mufson, et al., 2012,Storandt, et al., 2006), no studies have extensively characterized the molecular state of the MCI brain at the gene expression level.”
BackgroundBarone, E., Di Domenico, F., Sultana, R., Coccia, R., Mancuso, C., Perluigi, M., & Butterfield, D. A. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.03.020 · Cited by 124
“Conversely, the cerebellum is largely devoid of pathology and oxidative stress [45] [46] [47].”
BackgroundIdentifying incipient dementia individuals using machine learning and amyloid imaging
Mathotaarachchi, S., Pascoal, T. A., Shin, M., Benedet, A. L., Kang, M. S., Beaudry, T., Fonov, V. S., Gauthier, S., & Rosa-Neto, P. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.06.027 · Cited by 118
“As the earliest detectable clinical stage of the trajectory towards dementia, mild cognitive impairment (MCI) provides an attractive point of entry to disease modifying interventions (Markesbery, 2010).”
MIBG myocardial scintigraphy in pre-motor Parkinson's disease: a review.
Sakakibara, R., Tateno, F., Kishi, M., Tsuyusaki, Y., Terada, H., & Inaoka, T. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2013.11.001 · Cited by 111
“Some pathology-proven LBD patients have shown amnestic MCI before progressing to the core clinical features of DLB (dementia and spontaneous parkinsonism) [26].”
RNA and Oxidative Stress in Alzheimer’s Disease: Focus on microRNAs
Nunomura, A., & Perry, G. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/2638130 · Cited by 109
“However, in brains of patients with MCI and AD, a significant reduction in REST has been found in cortical and hippocampal neurons, where nuclear REST levels are positively correlated with a global cognitive measure.”
BackgroundInfluentialLiu, Y., Pan, N., Ma, Y., Zhang, S., Guo, W., Haihong, L., Zhou, J., Liu, G., & Gao, M. (2012) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31825a674d · Cited by 116
“Although amyloid plaques occur in both patients with aMCI and AD, plaques and neurofibrillary tangles in patients with AD are localized to brain areas that correspond to functions related to clinical symptoms including speech, memory or other essential cognitive difficulties.(29) Although the development of plaques in…”
BackgroundDi Domenico, F., Sultana, R., Tiu, G. F., Scheff, N. N., Perluigi, M., Cini, C., & Butterfield, D. A. (2010) · Brain Research · doi:10.1016/j.brainres.2010.03.085 · Cited by 106
“0006-8993/$ – see front matter © 2010 Elsevi doi:10.1016/j.brainres.2010.03.085 A B S T R A C T”
BackgroundInfluentialA critical review of chronic traumatic encephalopathy
Iverson, G. L., Gardner, A. J., McCrory, P., Zafonte, R., & Castellani, R. J. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.05.008 · Cited by 103
A Meta-Analysis of Alzheimer’s Disease Brain Transcriptomic Data
Patel, H., Dobson, R. J. B., & Newhouse, S. J. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-181085 · Cited by 95
Butterfield, D. A. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101049 · Cited by 93
“Epidemiology, Pathophysiology, and Pathogenesis An authoritative pathological exposition of AD and MCI has been reported by Nelson and Markesbery (Nelson and Markesbery, 2010; Markesbery, 2007; 2009) or other neuropathologists (Landau and Frosch,,2014; Malek-Ahmadi et al., 2018).”
BackgroundTremblay, C., St-Amour, I., Schneider, J., Bennett, D. A., & Calon, F. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31822c62cf · Cited by 95
Barone, E., Di Domenico, F., Cenini, G., Sultana, R., Cini, C., Preziosi, P., Perluigi, M., Mancuso, C., & Butterfield, D. A. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.01.005 · Cited by 96
“Indeed, hippocampus is broadly recognized as a main target of neurodegenerative damage during AD progression, presenting increased levels of oxidative stress, neuronal loss and marked atrophy in respect to whole brain [29–31].”
BackgroundNerve Growth Factor Pathobiology During the Progression of Alzheimer’s Disease
Mufson, E. J., Counts, S., Ginsberg, S. D., Mahady, L. J., Perez, S. E., Massa, S. M., Longo, F. M., & Ikonomović, M. D. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00533 · Cited by 100
“…clinically diagnosed with NCI or with MCI display amyloid plaque and NFT pathology similar to that seen in AD, challenging the pathologically-based concept that these lesions alone hasten dementia onset (Mufson and Kordower, 1999; Price and Morris, 1999; Markesbery, 2010; Mufson et al., 2016a,b).”
BackgroundThung, K.-H., Yap, P.-T., Adeli, E., Lee, S.-W., & Shen, D. (2018) · Medical Image Analysis · doi:10.1016/j.media.2018.01.002 · Cited by 89
“Post- ortem brain studies ( Markesbery, 2010; Petersen et al., 2006; icha et al., 2006; Cairns et al., 2015 ) on deceased MCI and AD subects also confirm that most of them developed a mixture of neuodegenerative diseases.”
Exercise-Related Changes of Networks in Aging and Mild Cognitive Impairment Brain
Huang, P., Fang, R., Li, B.-Y., & Chen, S.-D. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00047 · Cited by 82
“The distribution of amyloid deposits in MCI was reported to be intermediate between the changes in normal aging and AD brain (Markesbery, 2010).”
BackgroundMontero-Crespo, M., Domínguez-Álvaro, M., Alonso-Nanclares, L., DeFelipe, J., & Blazquez-Llorca, L. (2021) · Brain · doi:10.1093/brain/awaa406 · Cited by 89
“…tangles (NFTs) and aberrant amyloid-b deposition have been described as the main neuropathological hallmarks of Alzheimer’s disease, they have also been found in the aged brain with no apparent cognitive impairment (Mufson et al., 1999; Price et al., 2009; Markesbery, 2010; Ferrer, 2012).”
BackgroundMitochondrial Oxidative and Nitrosative Stress and Alzheimer Disease
Butterfield, D. A., & Boyd-Kimball, D. (2020) · Antioxidants · doi:10.3390/antiox9090818 · Cited by 85
“Pathology in MCI is similar to that in AD, albeit to a somewhat lesser extent [7].”
ResultBigger is better! Hippocampal volume and declarative memory performance in healthy young men
Pohlack, S. T., Meyer, P., Cacciaglia, R., Liebscher, C., Ridder, S., & Flor, H. (2014) · Brain Structure and Function · doi:10.1007/s00429-012-0497-z · Cited by 75
“Both conditions have been associated with impaired hippocampal functioning (Markesbery 2010; Cipolotti and Bird 2006).”
BackgroundSirtuin 1 and Alzheimer's disease: An up-to-date review
Rizzi, L., & Roriz-Cruz, M. (2018) · Neuropeptides · doi:10.1016/j.npep.2018.07.001 · Cited by 84
Lin, W., Gao, Q., Yuan, J., Chen, Z., Feng, C., Chen, W., Du, M., & Tong, T. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00077 · Cited by 78
“The pathology changes of AD begin several years before the first clinical symptoms, and mild cognitive impairment (MCI) is thought to be the prodromal stage of AD (Markesbery and Lovell, 2010).”
Rosano, C., Bennett, D. A., Newman, A. B., Venkatraman, V. K., Yaffe, K. S., Harris, T. B., Kritchevsky, S. B., & Aizenstein, H. J. (2012) · The Journals of Gerontology Series A · doi:10.1093/gerona/glr262 · Cited by 80
“The association of smaller GMv of the medial temporal area with gait disturbances complements the growing literature on the association of memory and gait (eg, Markesbery [27]).”
BackgroundPentón-Rol, G., Marín-Prida, J., & McCarty, M. F. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210408123807 · Cited by 73
“In addition to the amyloid theory of AD pathogenesis, other biological processes are involved in its etiology and progression, which includes an initial transition between normal aging and mild cognitive impairment, which is recognized as an early phase of memory dysfunction previous to AD development [133].”
Pathobiology of Cognitive Impairment in Parkinson Disease: Challenges and Outlooks
Jellinger, K. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010498 · Cited by 79
“In conclusion, the available autopsy data for PD-MCI revealed a heterogenous picture with the presence of various types of pathological changes similar to MCI in other diseases [386,387], in which the role of other pathologies should be further explored.”
BackgroundThe Role of the Human Entorhinal Cortex in a Representational Account of Memory
Schultz, H., Sommer, T., & Peters, J. (2015) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2015.00628 · Cited by 72
“Studies in humans underline its importance for memory: EC may be affected early in Alzheimer’s disease (AD) and mild cognitive impairment (MCI; deToledo-Morrell et al., 2004; Pihlajamäki et al., 2009; Markesbery, 2010; Khan et al., 2014).”
BackgroundA Chemical Analog of Curcumin as an Improved Inhibitor of Amyloid Abeta Oligomerization
Orlando, R. A., Gonzales, A. M., Royer, R. E., Deck, L. M., & Jagt, D. L. V. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031869 · Cited by 78
Fu, Z.-Q., Yang, Y., Song, J., Jiang, Q., Liu, Z.-C., Wang, Q., Zhu, L.-Q., Wang, J.-Z., & Tian, Q. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100687 · Cited by 63
“Moreover, the amount of NFT in the AD brains demonstrates a better correlation with dementia [12].”
Cocciolo, A., Domenico, F. D., Coccia, R., Fiorini, A., Cai, J., Pierce, W. M. J., Mecocci, P., Butterfield, D. A., & Perluigi, M. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.08.596 · Cited by 70
MSUT2 is a determinant of susceptibility to tau neurotoxicity
Guthrie, C. R., Greenup, L., Leverenz, J. B., & Kraemer, B. C. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr079 · Cited by 64
“Furthermore, MTL also plays an important role in memory encoding (17).”
BackgroundMinhas, S., Khanum, A., Riaz, F., Khan, S. A., & Alvi, A. (2018) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2017.2703918 · Cited by 59
Rosano, C., Aizenstein, H. J., Newman, A. B., Venkatraman, V. K., Harris, T. B., Ding, J., Satterfield, S., & Yaffe, K. S. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.04.033 · Cited by 68
“Numerous independent works, including our prior study, have shown that volume and function of the medial temporal lobe areas are related to cognitive impairment and dementia in older adults (Daulatzai, 2010; Markesbery, 2010; Rosano et al., 2007).”
Acevedo, B. P., Jagiellowicz, J., Aron, E. N., Marhenke, R., & Aron, A. P. (2017) · Cited by 115
Criteria for the neuropathological diagnosis of dementing disorders: routes out of the swamp?
Jellinger, K. A. (2009) · Acta Neuropathologica · doi:10.1007/s00401-008-0466-z · Cited by 60
“Although cognitively unimpaired subjects may show variable neocortical AD-related pathology [196,197], in general, the number of isocortical tangles correlates best with clinical dementia severity [198-204].”
BackgroundSynapse Stability in the Precuneus Early in the Progression of Alzheimer's Disease
Scheff, S. W., Price, D. A., Schmitt, F. A., Roberts, K. N., Ikonomovic, M. D., & Mufson, E. J. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-122353 · Cited by 59
“Several studies support the idea that the possible underlying substrates for aMCI are the accumulation of NFTs [11–13] and increased accumulation of NPs [14].”
Braak staging, plaque pathology, and APOE status in elderly persons without cognitive impairment
Mufson, E. J., Malek-Ahmadi, M., Perez, S. E., & Chen, K. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.10.012 · Cited by 57
Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairment
Dugger, B. N., Davis, K., Malek-Ahmadi, M., Hentz, J. G., Sandhu, S., Beach, T. G., Adler, C. H., Caselli, R. J., Johnson, T. A., Serrano, G. E., et al. (2015) · BMC Neurology · doi:10.1186/s12883-015-0403-4 · Cited by 58
“Although this study had limitations, such as the small sample size and the greater proportion of aMCI cases, perhaps due to the known prevalence of MCI subtypes [6, 38], it is the most comprehensive study to date analyzing a full range of pathologies among amnestic and nonamnestic MCI subjects.”
BackgroundResultWWOX Loss of Function in Neurodevelopmental and Neurodegenerative Disorders
Aldaz, C. M., & Hussain, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238922 · Cited by 62
Dewar, M., Pesallaccia, M., Cowan, N., Provinciali, L., & Sala, S. D. (2012) · Brain and Cognition · doi:10.1016/j.bandc.2011.12.005 · Cited by 66
“The asymptomatic and aMCI stages of the disease are characterised by isolated medial temporal lobe (MTL) pathology, starting in the transentorhinal region and gradually spreading to the entorhinal region as well as the hippocampus (Braak & Braak, 1991, 1995), and this pathology intensifies with AD disease progression…”
InfluentialNeurobiology of cognitive impairment in Parkinson’s disease
Jellinger, K. A. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.131 · Cited by 63
Jellinger, K. A. (2019) · Journal of Neural Transmission · doi:10.1007/s00702-019-02028-6 · Cited by 60
Keeney, J. T. R., Swomley, A. M., Harris, J. L., Fiorini, A., Mitov, M. I., Perluigi, M., Sultana, R., & Butterfield, D. A. (2011) · Neurotoxicity Research · doi:10.1007/s12640-011-9287-2 · Cited by 62
Garcia, G., Pinto, S., Ferreira, S., Lopes, D., Serrador, M. J., Fernandes, A., Vaz, A. R., Mendonça, A. D., Edenhofer, F., Malm, T., et al. (2022) · Cells · doi:10.3390/cells11213377 · Cited by 55
“To better follow patients with early neurocognitive complaints and their eventual progression to AD, the concept of mild cognitive impairment (MCI) based on AD biomarkers was considered clinically useful and shown to impact patient management [4,5].”
BackgroundCespón, J., Galdo‐Álvarez, S., Pereiro, A. X., & Díaz, F. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132774 · Cited by 56
“of clinical symptoms [3].”
Preclinical Stage Alzheimer's Disease Detection Using Magnetic Resonance Image Scans
Altay, F., Sánchez, G. R., Zhang‐James, Y., Faraone, S. V., Velipasalar, S., & Salekin, A. (2021) · Proceedings of the AAAI Conference on Artificial Intelligence · doi:10.1609/aaai.v35i17.17772 · Cited by 63
Kayano, M., Higaki, S., Satoh, J.-I., Matsumoto, K., Matsubara, E., Takikawa, O., & Niida, S. (2016) · Biomarker Research · doi:10.1186/s40364-016-0076-1 · Cited by 54
Complex network analysis of MCI-AD EEG signals under cognitive and resting state
Das, S. S., & Puthankattil, S. D. (2020) · Brain Research · doi:10.1016/j.brainres.2020.146743 · Cited by 58
A multimodal machine learning model for predicting dementia conversion in Alzheimer’s disease
Lee, M., Kim, H. W., Choe, Y. S., Yang, H. S., Lee, J., Lee, H., Yong, J. H., Kim, D., Lee, M., Kang, D. W., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-60134-2 · Cited by 62
Yang, X., Chen, Y.-H., Liu, L., Gu, Z., You, Y., Hao, J., Sun, N., & Gao, C. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107357 · Cited by 60
Evaluation of Cholinergic Deficiency in Preclinical Alzheimer’s Disease Using Pupillometry
Frost, S. M., Robinson, L., Rowe, C. C., Ames, D. J., Masters, C. L., Taddei, K., Rainey‐Smith, S. R., Martins, R. N., & Kanagasingam, Y. (2017) · Journal of Ophthalmology · doi:10.1155/2017/7935406 · Cited by 54
Morphological basis of Parkinson disease-associated cognitive impairment: an update
Jellinger, K. A. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-022-02522-4 · Cited by 55
“This study also confirmed a clear morphological heterogeneity in PD-MCI similar to that in MCI without PD (Markesbery 2010).”
ResultDowling, N. M., Tomaszewski Farias, S., Reed, B. R., Sonnen, J. A., Strauss, M. E., Schneider, J. A., Bennett, D. A., & Mungas, D. (2010) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617710001426 · Cited by 47
“This finding agrees with the hypothesized sequence of development of AD pathology wherein NFT pathology first emerges within medial temporal lobe structures (Markesbery, 2010) but ultimately progresses to include neocortex (Braak & Braak 1991, 1997).”
Tau Oligomer Pathology in Nucleus Basalis Neurons During the Progression of Alzheimer Disease
Tiernan, C. T., Mufson, E. J., Kanaan, N. M., & Counts, S. (2018) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlx120 · Cited by 48
Neuropathology in Parkinson’s disease with mild cognitive impairment
Jellinger, K. A. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0755-1 · Cited by 54
“The presently available scarce data in PD-MCI suggest a heterogenous neuropathology simular to those found in MCI cases without PD [9, 11–14], except the”
ResultSaied, I., Arslan, T., Chandran, S., Smith, C., Spires‐Jones, T. L., & Pal, S. (2020) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2020.3011359 · Cited by 45
“MCI has been defined in some follow up studies [30], [31] to be the earliest known stage where plaques and tangles”
BackgroundEndoplasmic reticulum stress induces spatial memory deficits by activating GSK ‐3
Li, L., Cao, J., Yang, S., Fu, Z., Zeng, P. H., Chu, J., Ning, L., Zhang, T., Shi, Y., Tian, Q., et al. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13626 · Cited by 47
“Previous studies have shown that the amount of NFTs, mainly composed of the hyperphosphorylated tau,(3,4) in the AD brains is correlated with the degree of dementia.(5,6) Studies also showed that b-amyloid (Ab), forming toxic oligomers that aggregate into amyloid plaques, was associated with age-related memory impairm…”
ResultElectrophysiological Correlates of Amnestic Mild Cognitive Impairment in a Simon Task
Cespón, J., Galdo‐Álvarez, S., & Díaz, F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081506 · Cited by 45
“The pathophysiological processes involved in Alzheimer’s disease (AD) are thought to take place before development of dementia [1].”
BackgroundCorsetti, V., Borreca, A., Latina, V., Giacovazzo, G., Pignataro, A., Krashia, P., Natale, F., Cocco, S., Rinaudo, M., Malerba, F., et al. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa039 · Cited by 42
Mild cognitive impairment in Parkinson's disease: current view
Jellinger, K. A. (2024) · Frontiers in Cognition · doi:10.3389/fcogn.2024.1369538 · Cited by 44
“However, there is a clear morphological heterogeneity in PD-MCI, similar to that in MCI cases without PD (Markesbery, 2010).”
InfluentialSun, Q., Hampel, H. J., Blennow, K., Lista, S., Levey, A. I., Tang, B., Li, R., & Shen, Y. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140177 · Cited by 47
“…proportion of MCI represents a transitional Accordingly, studies suggest that MCI subjects tend to progress to clinically probable AD at a rate of approximately 10%–15% per year [4, 5]. would be facilitated by easily accessible biomarkers Although most biomarkers of AD are currently measured [6,7].”
Triplett, J. C., Swomley, A. M., Cai, J., Klein, J. B., & Butterfield, D. A. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150417 · Cited by 39
“Differences in SP deposition and density are generally intermediate to AD pathology, but this can widely vary [8].”
BackgroundMild cognitive impairment in Parkinson disease: heterogenous mechanisms
Jellinger, K. A. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-012-0771-5 · Cited by 46
“…these latter cases, Alzheimer-like lesions are the most common pathology, infarctions and mixed pathologies also being present (Bennett et al. 2005; Markesbery 2010; Petersen et al. 2006; Schneider et al. 2009; Storandt et al. 2006), while up to 29% were reported to have developed non-AD primary…”
BackgroundResultInfluentialSafety of Nicergoline as an Agent for Management of Cognitive Function Disorders
Saletu, B., Garg, A., & Shoeb, A. (2014) · BioMed Research International · doi:10.1155/2014/610103 · Cited by 38
“It appears now that most amnestic mild cognitive impairment (aMCI) patients are on a pathway toward AD [25].”
BackgroundBraak stage and trajectory of cognitive decline in noncognitively impaired elders
Mufson, E. J., Malek‐Ahmadi, M. H., Snyder, N. L., Ausdemore, J., Chen, K., & Perez, S. E. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.03.003 · Cited by 39
“…(NFTs) and beta amyloid (Aβ) plaques, the two neuropathology hallmarks of Alzheimer’s disease (AD) (Bennett et al., 2002; Guillozet et al., 2003; Markesbery, 2010; Morris and Price, 2001; Morris et al., 2001; Mufson et al., 2016, 1999; Price et al., 2009; Tomlinson et al., 1970; Wilson et…”
BackgroundPlatero, C. A., Tobar, M. C., & Initiative, A. D. N. (2020) · Brain Imaging and Behavior · doi:10.1007/s11682-020-00366-8 · Cited by 39
“Mild cognitive impairment (MCI), the earliest clinically detectable phase of the trajectory toward dementia and AD, affects 15% to 20% of people older than 65 years (Markesbery 2010;”
Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases
Liu, J., Ting, J. P., Al-Azzam, S., Ding, Y., & Afshar, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062805 · Cited by 40
Xie, C., Bai, F., Yuan, B., Yu, H., Shi, Y., Yuan, Y., Wu, D., Zhang, Z., & Zhang, Z.-J. (2014) · Psychological Medicine · doi:10.1017/s0033291714002876 · Cited by 40
“Moreover, intermediate amounts of AD-related neuropathological findings, including amyloid deposition and neurofibrillary tangles, were also found in the mesial temporal and neocortical structures in aMCI patients relative to age-matched normal adults and patients with AD (Bourgeat et al. 2010; Markesbery, 2010).”
ResultDecline in Literacy and Incident AD Dementia Among Community-Dwelling Older Persons
Yu, L., Wilson, R. S., Han, S. D., Leurgans, S. E., Bennett, D. A., & Boyle, P. A. (2017) · Journal of Aging and Health · doi:10.1177/0898264317716361 · Cited by 36
“, 2011) and that AD pathology accumulates slowly over years or even decades prior to the onset of overt clinical symptoms (Markesbery, 2010).”
BackgroundTemporal course of neurodegenerative effects on cognition in old age.
Wilson, R. S., Capuano, A. W., Bennett, D., Schneider, J. A., & Boyle, P. A. (2016) · Neuropsychology · doi:10.1037/neu0000282 · Cited by 36
“Although these lesions are traditionally associated with dementia, they are also found in the brains of old persons who died with mild (Petersen et al., 2006; Markesbery, 2010) or no (Bennett et al., 2012) cognitive impairment.”
BackgroundRamshini, H., Mohammad‐Zadeh, M., & Ebrahim‐Habibi, A. (2015) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2015.04.038 · Cited by 35
Verdurand, M., & Zimmer, L. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.06.021 · Cited by 38
Staging Neurodegenerative Disorders: Structural, Regional, Biomarker, and Functional Progressions
Archer, T., Kostrzewa, R. M., Beninger, R. J., & Palomo, T. (2011) · Neurotoxicity Research · doi:10.1007/s12640-010-9190-2 · Cited by 34
“There is now a vast array of evidence that distinguishes the extent of regional atrophy, particularly medial temporal, biomarker changes, and cognitive decline in normal aging, MCI, and AD (cf., Jessen et al. 2009; Loewenstein et al. 2009; Markesbery 2010; Pievani et al. 2010), as well as early symptoms and signs, pro…”
BackgroundXie, H., Jiang, J., Cao, S., Xu, X., Zhou, J., Zhang, R., Huang, B., Lu, P., Peng, L., & Liu, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031373 · Cited by 34
“As a precursor to AD, MCI already exhibits abnormal protein aggregation [125], although to a lesser degree.”
Elder, M. K., Erdjument‐Bromage, H., Oliveira, M. M., Mamcarz, M., Neubert, T. A., & Klann, E. (2021) · Communications Biology · doi:10.1038/s42003-021-02324-6 · Cited by 40
Metadata
- Authors
- Markesbery, W. R.
- Affiliations
- University of Kentucky (US)
- Corresponding author
- Markesbery, William R.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2010-01-06
- Volume
- 19
- Issue
- 1
- Pages
- 221-228
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC2872776
- OpenAlex
- W1554171816
- Cited by
- 236
- References
- 35
- Citations by year
- 2026: 4 · 2025: 10 · 2024: 12 · 2023: 13 · 2022: 12 · 2021: 16 · 2020: 18 · 2019: 8 · 2018: 11 · 2017: 14 · 2016: 16 · 2015: 17 · 2014: 13 · 2013: 17 · 2012: 22
- FWCI
- 15.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Institute on Aging (P30AG028383, P01AG005119, AG0 5119)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
- Keywords
- mild cognitive impairment, Alzheimer's disease
- MeSH terms
- Age Factors, Alzheimer Disease, Animals, Cognition Disorders, Humans, Neurofibrillary Tangles, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.